Journal of Clinical Lipidology

Papers
(The TQCC of Journal of Clinical Lipidology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Hypolipidemia is associated with the severity of COVID-19251
The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction101
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group68
Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials68
Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association67
NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient55
Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy50
Ceramides and risk of major adverse cardiovascular events: A meta-analysis of longitudinal studies50
Viewing atherosclerosis through a crystal lens: How the evolving structure of cholesterol crystals in atherosclerotic plaque alters its stability48
The association between triglycerides and incident cardiovascular disease: What is “optimal”?40
Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)37
A simplified diagnosis algorithm for dysbetalipoproteinemia36
PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study36
Ketogenic diets, not for everyone36
Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two–Lipid Center Real-World Experience33
Saturated fats and cardiovascular health: Current evidence and controversies33
Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment32
Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial32
ABCG5 and ABCG8 genetic variants in familial hypercholesterolemia24
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association23
HDL proteome remodeling associates with COVID-19 severity22
Association between antecedent statin use and severe disease outcomes in COVID-19: A retrospective study with propensity score matching22
Patient acceptance of genetic testing for familial hypercholesterolemia in the CASCADE FH Registry21
Chylomicronemia syndrome: Familial or not?21
Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events20
Combined hyperlipidemia is genetically similar to isolated hypertriglyceridemia20
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials19
Low levels of cholesterol and the cholesterol type are not associated with depression: Results of a cross-sectional NHANES study19
Associations of GlycA and high-sensitivity C-reactive protein with measures of lipolysis in adults with obesity19
A catalog of the pathogenic mutations of LDL receptor gene in Japanese familial hypercholesterolemia19
Prevention of atherosclerotic cardiovascular disease in South Asians in the US: A clinical perspective from the National Lipid Association19
Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia18
PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization18
The first Japanese cases of familial hypercholesterolemia due to a known pathogenic APOB gene variant, c.10580 G>A: p.(Arg3527Gln)18
A mechanism-based operational definition and classification of hypercholesterolemia18
Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresi17
Guidance for the diagnosis and treatment of hypolipidemia disorders17
Quantile-specific heritability of high-density lipoproteins with implications for precision medicine17
Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study17
High prevalence of plasma lipid abnormalities in human and canine Duchenne and Becker muscular dystrophies depicts a new type of primary genetic dyslipidemia17
Comparison of nonfasting and fasting lipoprotein subfractions and size in 15,397 apparently healthy individuals: An analysis from the VITamin D and OmegA-3 TriaL17
Association between statin use and cognitive function: A systematic review of randomized clinical trials and observational studies17
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association16
Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial16
Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement f16
Real-world utilization of bempedoic acid in an academic preventive cardiology practice16
Association of high maternal triglyceride levels early and late in pregnancy with adverse outcomes: A retrospective cohort study15
Small interfering ribonucleic acid for cholesterol lowering – Inclisiran15
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia15
Pediatric cholesterol screening practices in 9- to 11-year-olds in a large midwestern primary care setting14
Hypertriglyceridemia during hospitalization independently associates with mortality in patients with COVID-1914
Triglyceride-lowering and anti-inflammatory mechanisms of omega-3 polyunsaturated fatty acids for atherosclerotic cardiovascular risk reduction14
Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies14
Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States13
Association of apolipoprotein C3 with insulin resistance and coronary artery calcium in patients with type 1 diabetes13
Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort13
Effect of bariatric surgery on plasma levels of oxidised phospholipids, biomarkers of oxidised LDL and lipoprotein(a)13
Negative impact of COVID-19 pandemic on the lifestyle and management of patients with homozygous familial hypercholesterolemia13
Closing the gap: Identification and management of familial hypercholesterolemia in an integrated healthcare delivery system13
Long-term outcomes after acute myocardial infarction in patients with familial hypercholesterolemia: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction program12
Lipoprotein(a) and inflammation- pathophysiological links and clinical implications for cardiovascular disease12
Gene–environment interaction between APOA5 c.553G>T and pregnancy in hypertriglyceridemia-induced acute pancreatitis11
Statin use and fall-related hospitalizations among residents of long-term care facilities: A case-control study11
Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 211
Familial hypercholesterolemia in Mexico: Initial insights from the national registry11
Effect of pharmacist interventions on reducing low-density lipoprotein cholesterol (LDL-C) levels: A systematic review and meta-analysis11
Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysis11
APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia11
Clinical, genetic profile and therapy evaluation of 55 children and 5 adults with sitosterolemia10
Characterizing lipid profiles associated with asymptomatic intracranial arterial stenosis in rural-dwelling adults: A population-based study10
Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction10
Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience10
Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial10
Comprehensive (apo)lipoprotein profiling in patients with genetic hypertriglyceridemia using LC-MS and NMR spectroscopy10
The economic impact of familial hypercholesterolemia on productivity9
Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction9
C3 and alternative pathway components are associated with an adverse lipoprotein subclass profile: The CODAM study9
Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association9
Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic9
Characteristics and trends of PCSK9 inhibitor prescription fills in the United States9
Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the Multi-Ethnic Study of Atherosclerosis (MESA)9
Health-related quality of life in homozygous familial hypercholesterolemia: A systematic review and meta-analysis8
The triglyceride to HDL-cholesterol ratio and chronic graft failure in renal transplantation8
Nut consumption, risk of cardiovascular mortality, and potential mediating mechanisms: The Women's Health Study8
Mustard oil and cardiovascular health: Why the controversy?8
Partial lipodystrophy, severe dyslipidaemia and insulin resistant diabetes as early signs of Werner syndrome8
Misinterpreting data in lipidology in the era of COVID-198
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial8
Sex‐related differences in premature cardiovascular disease in familial hypercholesterolemia8
Intima-media thickness in treated and untreated patients with and without familial hypercholesterolemia: A systematic review and meta-analysis8
JCL roundtable: Lipids and inflammation in atherosclerosis8
JCL roundtable: South Asian atherosclerotic risk8
Functional profiling of LDLR variants: Important evidence for variant classification8
Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD8
Lipoprotein (a) is associated with poor long-term prognosis in patients aged 80 years and older with acute coronary syndrome8
CERT2 ceramide- and phospholipid-based risk score and major adverse cardiovascular events: A systematic review and meta-analysis8
Mental status and physical activity in patients with homozygous familial hypercholesterolemia: A subgroup analysis of a nationwide survey (A-HIT1 registry)8
Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of India8
Cholestasis as a dominating symptom of patients with CYP27A1 mutations: An analysis of 17 Chinese infants7
Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT7
Lower triglyceride levels are associated with better endothelial function7
Impact of small dense low-density lipoprotein cholesterol on cholesterol crystals in patients with acute coronary syndrome: An optical coherence tomography study7
Free fatty acids, cardiovascular disease, and mortality in the Multi-Ethnic Study of Atherosclerosis7
Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia: Implications for clinical diagnosis7
Awareness, diagnosis and treatment of heterozygous familial hypercholesterolemia (HeFH) – Results of a US national survey7
Sex differences in LDL-C response to PCSK9 inhibitors: A real world experience7
Lipidomic changes of LDL after consumption of Camelina sativa oil, fatty fish and lean fish in subjects with impaired glucose metabolism—A randomized controlled trial7
Update on the omega-3 fatty acid trial landscape: A narrative review with implications for primary prevention7
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Pre7
Evolocumab in patients with homozygous familial hypercholesterolemia in India7
Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH)7
Prevalence of genetically verified familial hypercholesterolemia among young (<45 years) Norwegian patients hospitalized with acute myocardial infarction7
Vasomotor symptoms and lipids/lipoprotein subclass metrics in midlife women: Does level of endogenous estradiol matter? The SWAN HDL Ancillary Study6
Chronic kidney disease and statin eligibility6
Plasma fatty acid profiles: Relationships with sex, age, and state-reported heart disease mortality rates in the United States6
The impact of dyslipidemia on early markers of endothelial and renal dysfunction in children6
Effects of a 6-month dietary-induced weight loss on erythrocyte membrane omega-3 fatty acids and hepatic status of subjects with nonalcoholic fatty liver disease: The Fatty Liver in Obesity study6
Importance of the triglyceride level in identifying patients with a Type III Hyperlipoproteinemia phenotype using the ApoB algorithm6
Effectiveness of medical nutrition therapy in the management of adult dyslipidemia: A systematic review and meta-analysis6
Elevated LDL-cholesterol levels among lean mass hyper-responders on low-carbohydrate ketogenic diets deserve urgent clinical attention and further research6
Extreme elevations of low-density lipoprotein cholesterol with very low carbohydrate, high fat diets6
Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis6
Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects6
Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002–20166
Concerns regarding NMR lipoprotein analyses performed on the Nightingale heath platform – Focus on LDL subclasses6
Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia6
Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial6
Utility of metabolic syndrome as a risk enhancing factor in decision of statin use6
High lipoprotein(a) levels predict severity of coronary artery disease in patients hospitalized for acute myocardial infarction. Data from the French RICO survey6
Relative effect of hypertriglyceridemia on non-HDLC and apolipoprotein B as cardiovascular disease risk markers6
Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers6
Applying an LDL-C threshold-based approach to identify individuals with familial hypercholesterolemia6
Are statins safe in patients with COVID-19?6
Familial hypercholesterolemia related admission for acute coronary syndrome in the United States: Incidence, predictors, and outcomes6
Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease5
Impact of a virtual lipid clinic on lipid-lowering therapy, LDL cholesterol levels, and outcomes in patients with acute coronary syndrome5
Familial hypobetalipoproteinemia caused by homozygous loss-of-function mutations in PCSK9: A case report5
Measurement of apolipoprotein B levels helps in the identification of patients at risk for hypertriglyceridemic pancreatitis5
Is hypertriglyceridemia a reliable indicator of cholesterol-depleted Apo B particles?5
Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy5
The longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants5
Managing cardiometabolic risk factors across a woman's lifespan: A lipidologist's perspective5
Ancestry-specific profiles of genetic determinants of severe hypertriglyceridemia5
Reference values for the triglyceride to high-density lipoprotein ratio and its association with cardiometabolic diseases in a mixed adult population: The ELSA-Brasil study5
The changing pattern of statin use in people with dementia: A population-based study5
Serum lipoprotein(a) and risk of mortality in patients on peritoneal dialysis5
Preβ1-high-density lipoprotein metabolism is delayed in patients with chronic kidney disease not on hemodialysis5
Diabetes and kidney dysfunction markedly alter the content of sphingolipids carried by circulating lipoproteins5
Atorvastatin-associated rhabdomyolysis in a patient with a novel variant of the SLCO1B1 gene: A case report5
Hyperlipidemia and risk for preclampsia5
Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model5
Atherosclerotic cardiovascular disease in hyperalphalipoproteinemia due to LIPG variants5
Perimenopausal transdermal estradiol replacement reduces serum HDL cholesterol efflux capacity but improves cardiovascular risk factors5
Prevalence, severity and management of hypertriglyceridemia-associated pancreatitis; A 7-year retrospective cohort study at Canadian quaternary care hospitals5
A cautionary tale: Is this APOB whole-gene duplication actually pathogenic?4
BIO89-100, a GlycoPEGylated FGF21 Analog, Improved Serum Lipids and Extended Half-Life in a Controlled Single Ascending Dose Trial in Healthy Subjects†4
Lipid profiles and hypertriglyceridemia among transgender and gender diverse adults on gender-affirming hormone therapy4
Coronary computed tomography angiography evaluation of plaque morphology and its relationship to HDL and total cholesterol to HDL ratio4
Attainment of low-density lipoprotein cholesterol goals in patients treated with combination therapy: A retrospective cohort study in primary care4
Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study4
Circulating GPIHBP1 levels and microvascular complications in patients with type 2 diabetes: A cross-sectional study4
Adherence to lipid monitoring and its impact on treatment intensification of LDL-C lowering therapies at an urban academic medical center4
Genetic variants in SUSD2 are associated with the risk of ischemic heart disease4
Monocyte phenotyping and management of lipoprotein X syndrome4
Identifying reference values for serum lipids in Chinese children and adolescents aged 6–17 years old: A national multicenter study4
Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials4
Prevalence and significance of risk enhancing biomarkers in the United States population at intermediate risk for atherosclerotic disease4
The importance of cascade genetic screening for diagnosing autosomal dominant hypercholesterolemia: Results from twenty years of a national screening program in Norway4
Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-194
Management of diabetic dyslipidemia in Indians: Expert consensus statement from the Lipid Association of India4
Involvement of a homozygous exon 6 deletion of LMF1 gene in intermittent severe hypertriglyceridemia4
Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system4
Lower levels of low-density lipoprotein cholesterol are associated with a lower prevalence of thin-cap fibroatheroma in statin-treated patients with coronary artery disease4
Corneal confocal microscopy identifies small nerve fibre damage in patients with hypertriglyceridemia4
GPIHBP1 autoantibody is an independent risk factor for the recurrence of hypertriglyceridemia-induced acute pancreatitis4
The ZPR1 genotype predicts myocardial infarction in patients with familial hypercholesterolemia4
Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review4
Incorporation of genetic testing significantly increases the number of individuals diagnosed with familial hypercholesterolemia4
A case of hyperchylomicronemia associated with GPIHBP1 autoantibodies and fluctuating thyroid autoimmune disease4
Nutrition interventions for youth with dyslipidemia: a National Lipid Association clinical perspective4
The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia4
A retrospective cohort study evaluating the relationship between statin medication adherence and economic outcomes in commercial health plans3
The epidemic of atherosclerotic cardiovascular disease in India3
Longitudinal changes in HDL-cholesterol concentration are associated with different risk factors in primiparous and nulliparous young women: The NHLBI Growth and Health Study (NGHS)3
Remnant cholesterol and risk of myocardial infarction in patients with coronary artery disease undergoing revascularization3
Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia3
Free fatty acids and heart failure in the Multi-Ethnic Study of Atherosclerosis (MESA)3
Lipoprotein(a), metabolic profile and new-onset type 2 diabetes in patients with familial combined hyperlipidemia: A 9 year follow-up study3
LDL receptor and pathogen processes: Functions beyond normal lipids3
Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome3
Multiple tendon ruptures associated with statin therapy3
Prevention: The past, present, and future of medicine and society3
JCL Roundtable: Global Think Tank on Lipoprotein(a)3
Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries: An expert panel discussion3
Impact of small dense low-density lipoprotein cholesterol and triglyceride-rich lipoproteins on plaque rupture with ST-segment elevation myocardial infarction3
Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemia3
Cardiometabolic risk factors in siblings from a statewide screening program3
Severe hypertriglyceridemia secondary to splice-site and missense variants in LMF1 in three patients from Ecuador3
†Safety and Efficacy of Bempedoic Acid in Patients with Renal Impairment3
Recommended and observed statin use among U.S. adults – National Health and Nutrition Examination Survey, 2011-20183
JCL roundtable: Healthy ethnic diets3
Failure of cosegregation between a rare STAP1 missense variant and hypercholesterolemia3
Comparison of two polygenic risk scores to identify non-monogenic primary hypocholesterolemias in a large cohort of Italian hypocholesterolemic subjects3
Temporal decline in non–high-density lipoprotein cholesterol in subjects with diabetes mellitus without atherosclerotic cardiovascular disease3
Quantifying the contribution of lipoprotein(a) to all apoB containing particles3
Fasting serum free glycerol concentration is a potential surrogate marker of visceral obesity and insulin sensitivity in middle-aged Japanese men3
Monogenic and polygenic causes of low and extremely low LDL-C levels in patients referred to specialty lipid clinics: Genetics of low LDL-C3
Forty year follow-up of three patients with complete absence of apolipoprotein B-containing lipoproteins3
Non-high-density lipoprotein cholesterol and mortality among peritoneal dialysis patients3
Lipid levels, apolipoproteins, and risk of incident atrial fibrillation in men: A report from the Kuopio Ischaemic Heart Disease Risk Factor Study (KIHD)3
Family history of diabetes determines the association of HOMA-IR with fasting and postprandial triglycerides in individuals with normal glucose tolerance3
The Relationship of Alcohol Consumption and HDL Metabolism in the Multiethnic Dallas Heart Study3
Reduced Expression of Angiopoietin-Like Protein 3 via RNA Interference with ARO-ANG3 Produces Prolonged Reductions in LDL-C and Triglycerides in Dyslipidemic Patients3
Evaluating the role of statins in prevention of preeclampsia: deeper insights into maternal cardiometabolic changes3
A retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients3
Statins, lipids and dementia?3
Lipoprotein(a) levels in children with homozygous familial hypercholesterolaemia: A cross-sectional study3
Novel PPARG mutation in multiple family members with chylomicronemia3
0.035285949707031